Botulinum Toxin Therapy for Limb Dystonias
Authors
Affiliations
We investigated the effectiveness of botulinum toxin in 17 patients with limb dystonias (10 with occupational cramps, three with idiopathic dystonia unrelated to activity, and two each with post-stroke and parkinsonian dystonia) in a placebo-controlled, blinded study. We identified affected muscles clinically and by recording the EMG from implanted wire electrodes at rest and during performance of tasks that precipitated abnormal postures. There were three injections given with graded doses of toxin (average doses, 5 to 10, 10 to 20, and 20 to 40 units per muscle) and one with placebo, in random order. Subjective improvement occurred after 53% of injections of botulinum toxin, and this was substantial in 24%. Only one patient (7%) improved after placebo injection. Subjective improvement occurred in 82% of patients with at least one dose of toxin, lasting for 1 to 4 months. Response rates were similar between clinical groups. Objective evaluation failed to demonstrate significant improvement following treatment with toxin compared with placebo. The major side effect was transient focal weakness after 53% of injections of toxin.
di Biase L, Di Santo A, Caminiti M, Pecoraro P, Di Lazzaro V Life (Basel). 2022; 12(2).
PMID: 35207493 PMC: 8875209. DOI: 10.3390/life12020206.
Botulinum Toxin Therapy in Writer's Cramp and Musician's Dystonia.
Zakin E, Simpson D Toxins (Basel). 2021; 13(12).
PMID: 34941736 PMC: 8708945. DOI: 10.3390/toxins13120899.
Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies.
Tambasco N, Filidei M, Nigro P, Parnetti L, Simoni S Toxins (Basel). 2021; 13(12).
PMID: 34941718 PMC: 8706367. DOI: 10.3390/toxins13120881.
Treatment of focal hand dystonia: current status.
Gupta N, Pandey S Neurol Sci. 2021; 42(9):3561-3584.
PMID: 34213695 DOI: 10.1007/s10072-021-05432-7.
Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation.
Bledsoe I, Viser A, San Luciano M Neurotherapeutics. 2020; 17(4):1622-1644.
PMID: 33095402 PMC: 7851280. DOI: 10.1007/s13311-020-00944-0.